Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Yang G, Wang Y, Tian J, Liu JP
Published in PLoS ONE
Methodology
Systematic review and meta-analysis of 20 randomised trials of huperzine A in Alzheimer's disease with MMSE and ADL endpoints
Key Findings
Huperzine A improved MMSE and activities of daily living scores versus placebo, but all trials had unclear or high risk of bias and effect sizes were inflated in lower-quality studies.
Conclusions
Apparent cognitive benefit of huperzine A is undermined by pervasive methodological weakness.
Limitations
High risk of bias; nearly all trials conducted in one region; small samples.
Supplements Studied
Huperzine A improved MMSE and activities of daily living scores versus placebo, but all trials had unclear or high risk of bias.
Outcomes Measured
Huperzine A improved MMSE scores versus placebo, but all trials had unclear or high risk of bias.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.